Clostridium difficileAssociated Disease Treatment Response Depends on Definition of Cure
To the Editor-We commend Zar et al. [1] for their recent study comparing oral metronidazole with oral vancomycin for first line therapy of Clostridium difficileassociated disease (CDAD). In this era, in which the incidence and severity of CDAD are increasing [2] , the timing could not be better to readdress this important clinical question. Recent observational data have called into question the presumed equivalence of these 2 drugs for the initial treatment of CDAD [3, 4] , which was originally established by nonblinded but prospective randomized trials conducted in the 1980s and early 1990s [5, 6] . Zar et al. [1] addressed the lack of prior study blinding and reported on a randomized, double-blinded trial completed in 2002 that involved 1150 patients and showed a difference in outcome among patients with severe CDAD. However, we believe that the definition used for cure may compromise the validity of their conclusion that vancomycin is superior to metronidazole in treating individuals with severe disease but not in treating those with mild CDAD.
Zar et al. [1] used an aggregate clinical and microbiological end point to assess efficacy, which consisted of diarrhea resolution by the sixth day of treatment, in addition to clearance of C. difficile toxin from stool specimens obtained on the sixth and tenth days of treatment [1] . By this definition, detection of C. difficile toxin in the day 6 stool specimen would constitute evidence of treatment failure, despite diarrhea resolution. However, most clinicians and previous clinical trials have used only clinical criteria for determining the success of anti-C. difficile treatment. Persistence of C. difficile toxin in stool specimens despite diarrhea resolution is a well-documented phenomenon; however, it is of uncertain clinical significance [6] . A previous study also showed that vancomycin was associated with higher rates of toxin clearance than was metronidazole, but vancomycin was not associated with a lower risk of recurrence [7] . Because of its lack of prognostic value, stool toxin testing after resolution of diarrhea is not recommended for a "test of cure" [8] .
Expert opinion supports the use of enterally administered vancomycin over the use of metronidazole in treating patients with severe disease on the basis of higher intracolonic drug concentrations, lower risk of bacterial resistance, and, possibly, faster clinical response [9] . Although it is not clear how the addition of toxin testing to the cure definition could selectively favor vancomycin over metronidazole for patients with severe CDAD but not for patients with mild CDAD, we would, nonetheless, be keenly interested in seeing a reanalysis of the data using a definition of cure based on clinical response alone, to make a more uniform comparison with prior CDAD treatment trials.
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Reply to Bishara et al., Huggan et al., and Lawrence et al.
To the Editor-We appreciate the insightful comments found in 3 letters [1] [2] [3] published in this issue of Clinical Infectious Diseases regarding our recently published article [4] . We agree with the concerns that isolated Clostridium difficile toxin A positivity may not be a relevant outcome in the absence of our other clinical end points of diarrhea, colectomy, and/or death. Table 1 shows the specific reasons that each patient was assigned to an outcome of treatment failure. Of note, toxin A positivity was the sole reason for treatment failure in only patients 84 and 99. We also agree that an intention-to-treat analysis including the early deaths in randomized patients would be useful. Table  2 shows the results obtained if patients 84 and 99 are reassigned to an outcome of cure and the 8 early deaths that are discussed in our article are included in the analysis. Of note is that vancomycin still appears to be superior to metronidazole with respect to the overall cure rate, as well as with respect to the cure rate for patients with severe disease.
Huggan and Murdoch [2] raise an important concern about concomitant antibiotic use. If, in spite of our randomization, patients in the metronidazole group had received antibiotics more commonly or more recently than patients in the vancomycin group, this may have lead to more treatment failures in the metronidazole group. To address this, table 3 demonstrates 4 categories of concomitant antibiotic use, stratified by treatment arm and disease severity. Within each treatment arm and disease severity category, there was no statistically significant difference between patients who experienced cure and patients who experienced treatment failure with respect to when they had last received antibiotics.
We acknowledge that our severity assessment score had not been prospectively evaluated, but as stated in our article [4] , other authors have subsequently reported many of the criteria that we selected to be valid predictors of treatment failure and/ or relapse. As yet, there is no universally accepted definition of severe C. difficileassociated diarrhea, although the recently published recommendations from the Ad Hoc Clostridium difficile Surveillance Working Group may be a step towards correcting this [5] .
We agree with the concern that any increased vancomycin use that our study
